Expect patent-heavy pharma acquisitions following Novartis’ $13 billion consumer healthcare divestment
This week saw the headline-grabbing multi-billion dollar sell-off by Novartis of its consumer healthcare business. Reflecting the Swiss entity’s desire to focus resources on strengthening its position in higher-priority therapeutic spaces, the deal…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.